Markets:

Overview

News

Currencies

International

Treasuries

Jaguar Health, Inc. - Common Stock (NQ:JAGX)

3.200 -0.350 (-9.86%)

Streaming Delayed Price Updated: 3:29 PM EDT, Jun 1, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Jaguar Health, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

22 23 Next >

JAGX Stock Earnings: Jaguar Health Misses EPS, Misses Revenue for Q2 2024 ↗

August 13, 2024

JAGX stock results show that Jaguar Health missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.

Via InvestorPlace

Why Jaguar Health (JAGX) Stock Is Down 15% ↗

August 13, 2024

Jaguar Health shares are trading lower by 15.4% during Tuesday's session. The company reported worse-than-expected second-quarter results.

Via Benzinga

Jaguar Health Reports Second Quarter 2024 Financial Results

August 13, 2024

Via ACCESSWIRE

REMINDER: Jaguar Health to Hold Investor Webcast Tuesday, August 13th at 8:30 AM Eastern to Review Q2 Earnings and Further Review Phase 3 OnTarget Trial’s Clinically Meaningful Results in Breast and Lung Cancer Patients

August 12, 2024

Via ACCESSWIRE

Jaguar Health Issues Shareholder Letter: Company to Explore Approval Pathway for Crofelemer in Breast and Lung Cancer Based on Phase 3 Results - Investor Webcast August 13th Will Review Q2 Earnings and Further Review OnTarget Trial’s Clinically Meaningful

August 05, 2024

Via ACCESSWIRE

Elaine Elisabetsky, PhD, Member of Jaguar Health's Mental Health Entheogen Therapeutics Initiative, to Speak August 2nd About Plant-Based Medicines Used to Manage Schizophrenia at the University of Illinois Chicago College of Pharmacy

August 02, 2024

Via ACCESSWIRE

Issuance of New European Patent Bolsters IP Protection for Jaguar Health in the Treatment of Congenital Diarrheal Disorders (CDDs)

July 31, 2024

Via ACCESSWIRE

Why Jaguar Health Stock Is Crashing ↗

July 23, 2024

Jaguar Health shares are falling Tuesday after the company announced its phase 3 OnTarget trial did not meet its primary endpoint. Here's a look at the details:

Via Benzinga

Jaguar Health Regains Compliance with Nasdaq's Bid Price Requirement

June 26, 2024

Via ACCESSWIRE

Two Investigator-Initiated Responder Analysis Trials of Jaguar Health's Crofelemer Show Significant Positive Results for Chronic Refractory Diarrhea in IBS-D: Data Accepted for Presentation at American College of Gastroenterology 2024 Annual Meeting

August 01, 2024

Via ACCESSWIRE

Gold Moves Higher; Coca-Cola Increases FY24 Forecast ↗

July 23, 2024

Via Benzinga

Why Is Azitra (AZTR) Stock Up 315% Today? ↗

July 23, 2024

Azitra stock is up on Tuesday alongside heavy trading of AZTR shares after it provided investors with an update on new patents.

Via InvestorPlace

Spot Ethereum ETFs: 9 Tickers to Watch as New Funds Start Trading ↗

July 23, 2024

Spot Ethereum ETFs have started trading on Tuesday marking a major milestone for fans of the crypto and Ethereum blockchain.

Via InvestorPlace

Topics ETFs

Why Is Serve Robotics (SERV) Stock Down Today? ↗

July 23, 2024

Serve Robotics stock is down on Tuesday after the company revealed the pricing of warrants for SERV shares in a private placement.

Via InvestorPlace

Jaguar Health Reports Approval of All Proposals at June 2024 Annual Meeting of Stockholders

June 21, 2024

Via ACCESSWIRE

Why Comcast Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

July 23, 2024

Via Benzinga

Why Is Jaguar Health (JAGX) Stock Down 55% Today? ↗

July 23, 2024

Jaguar Health stock is down on Tuesday as JAGX investors react to failed results from a Phase 3 clinical trial of crofelemer.

Via InvestorPlace

Crude Oil Down 2%; GE Aerospace Earnings Top Views ↗

July 23, 2024

Via Benzinga

US Stocks Edge Higher; General Motors Posts Upbeat Earnings ↗

July 23, 2024

Via Benzinga

Jaguar Health Reports Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer

July 23, 2024

Via ACCESSWIRE

Jaguar Health to Report Phase 3 OnTarget Trial Results for Its Cancer Supportive Care Drug Crofelemer on July 23rd and Hold Investor Webcast that Morning

July 18, 2024

Via ACCESSWIRE

Issuance of New European & Australian Patents Bolster IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS) and Congenital Diarrheal Disorders (CDDs)

July 08, 2024

Via ACCESSWIRE

Jaguar Health to Report Pivotal Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer on or Before July 23, 2024

June 12, 2024

Via ACCESSWIRE

Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

June 07, 2024

Via ACCESSWIRE

Nasdaq Stocks Soaring to the Top with Strategic Splits: NVDA, INBS, JAGX, SINT, GWAV

June 04, 2024

Via AB Newswire

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

May 30, 2024

Via Benzinga

Jaguar Health Executes Out-License Deal with Joint Venture Magdalena Biosciences for Botanical Drug Candidate for Schizophrenia

May 29, 2024

Via ACCESSWIRE

Investigator-Initiated Trial of Jaguar Health’s Crofelemer Yields Positive Results for Functional Diarrhea

May 28, 2024

Via ACCESSWIRE

What's Going On With Jaguar Health Stock? ↗

May 23, 2024

Jaguar Health shares are falling after the stock effected a reverse split at an exchange ratio of 1-for-60 Thursday, in order to support the company's compliance with Nasdaq listing standards.

Via Benzinga

Jaguar Health to Initiate Commercial Footprint in Cancer Supportive Care at American Society of Clinical Oncology (ASCO) Annual Meeting with Exhibit Booth for FDA-Approved Gelclair Oral Mucositis Product

May 23, 2024

Via ACCESSWIRE

< Previous 1 2 3 4 5 6 7 8 9

...

22 23 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.